[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on 09/01/2025. He received 264 restricted stock units that vested (reported as 264 shares acquired at $0), increasing his holdings to 45,087 shares. On the same date he disposed of 139 shares at a reported price of $67.42, leaving 44,948 shares beneficially owned after the transactions. The disclosure notes the RSU award was granted on November 2, 2021, with an initial 25% vesting on September 1, 2022, and the remaining 75% vesting quarterly over the following three years.

Positive

• Vesting of 264 RSUs increased the reporting person’s direct ownership, reflecting employee compensation realization
• Clear disclosure of the original grant date and vesting schedule provides transparency

Negative

• Disposition of 139 shares at $67.42 reduced direct holdings, representing a small insider sale

Insights

Securities Analyst

TL;DR: Insider received vested RSUs and sold a small number of shares; overall change is minor and routine.

The filing shows a routine vesting event and a small disposition by the Chief Legal Officer. Acquisition of 264 vested RSUs increased direct ownership to 45,087 shares before the sale. The sale of 139 shares at $67.42 reduced holdings to 44,948 shares. These transactions reflect standard compensation vesting and a small liquidity event rather than a material shift in ownership or company control.

Corporate Governance Expert

TL;DR: Transactions are compensation-related vesting and a minor sale; governance implications are limited.

The Form 4 discloses compensation-driven vesting from a 2021 RSU grant and a contemporaneous small disposal. The vesting schedule described is standard (25% then quarterly vesting over three years). There is no indication of acceleration, pledge, or change in relationship to the issuer. From a governance perspective, these are routine insider transactions with no apparent red flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saia John G.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		M		264	A	$0	45,087	D
Common Stock	09/01/2025		F		139(1)	D	$67.42	44,948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/01/2025		M			264	(2)	(1)	Common Stock	264	$0	0	D

Explanation of Responses:

1. Not applicable for Restricted Stock Units.

2. The restricted stock unit award was granted on November 2, 2021, and vested 25% of the shares subject to such award on September 1, 2022. The remaining 75% of the shares subject to such award vests in equal installments on each quarterly anniversary of September 1, 2022 during the three-year period thereafter.

Remarks:

	/s/ John G. Saia	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed this Form 4 for Guardant Health (GH)?

The Form 4 was filed by John G. Saia, identified as Chief Legal Officer and a director.

What transactions did John G. Saia report on 09/01/2025?

He reported acquisition of 264 shares from vested restricted stock units at $0 and a disposition of 139 shares at $67.42.

How many Guardant Health shares does Saia beneficially own after these transactions?

Following the reported transactions, he beneficially owns 44,948 shares.

When was the restricted stock unit award granted and what was its vesting schedule?

The RSU award was granted on November 2, 2021; 25% vested on September 1, 2022, and the remaining 75% vested in equal quarterly installments over the next three years.

Do these transactions indicate a change in control or significant ownership shift?

No. The filing shows routine vesting and a small sale that do not indicate a change in control or material ownership shift.